JP2005536525A - 制御された沈澱（再結晶化）法を用いて、製造された結晶質薬物粒子 - Google Patents

制御された沈澱（再結晶化）法を用いて、製造された結晶質薬物粒子 Download PDF

Info

Publication number
JP2005536525A
JP2005536525A JP2004526104A JP2004526104A JP2005536525A JP 2005536525 A JP2005536525 A JP 2005536525A JP 2004526104 A JP2004526104 A JP 2004526104A JP 2004526104 A JP2004526104 A JP 2004526104A JP 2005536525 A JP2005536525 A JP 2005536525A
Authority
JP
Japan
Prior art keywords
particles
drug
particle
crystalline
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004526104A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005536525A5 (enExample
Inventor
スベンソン，ソンケ
ジェイ． タッカー，クリストファー
イー． ヒット，ジェイムス
Original Assignee
ダウ グローバル テクノロジーズ インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダウ グローバル テクノロジーズ インコーポレイティド filed Critical ダウ グローバル テクノロジーズ インコーポレイティド
Publication of JP2005536525A publication Critical patent/JP2005536525A/ja
Publication of JP2005536525A5 publication Critical patent/JP2005536525A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
JP2004526104A 2002-08-06 2003-07-14 制御された沈澱（再結晶化）法を用いて、製造された結晶質薬物粒子 Pending JP2005536525A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/213,907 US20040028746A1 (en) 2002-08-06 2002-08-06 Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
PCT/US2003/021882 WO2004012710A1 (en) 2002-08-06 2003-07-14 Crystalline drug particles prepared using a controlled precipitation (recrystallization) process

Publications (2)

Publication Number Publication Date
JP2005536525A true JP2005536525A (ja) 2005-12-02
JP2005536525A5 JP2005536525A5 (enExample) 2006-08-31

Family

ID=31494557

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004526104A Pending JP2005536525A (ja) 2002-08-06 2003-07-14 制御された沈澱（再結晶化）法を用いて、製造された結晶質薬物粒子

Country Status (8)

Country Link
US (1) US20040028746A1 (enExample)
EP (1) EP1545463B1 (enExample)
JP (1) JP2005536525A (enExample)
CN (1) CN100356905C (enExample)
AT (1) ATE537815T1 (enExample)
AU (1) AU2003249195A1 (enExample)
CA (1) CA2494277A1 (enExample)
WO (1) WO2004012710A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
CN114394909B (zh) * 2021-12-31 2024-06-07 大连新阳光材料科技有限公司 对氨基苯甲酸微粉的制备方法
PT4489884T (pt) 2023-01-18 2025-10-15 Nanoform Finland Oyj Um método para cristalização de ingredientes farmacêuticos ativos

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
SE9501384D0 (sv) * 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
US5715642A (en) * 1995-08-16 1998-02-10 Steel Framing Supply Steel-frame system and member
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
US6869617B2 (en) * 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
EP1436057B1 (en) * 2001-10-17 2006-04-19 E.I. du Pont de Nemours and Company Rotor-stator apparatus and process for the formation of particles

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5005004893, ＰＯＺＡＲＮＳＫＹ Ｇ Ａ ｅｔ ａｌ．, ＣＯＬＬＯＩＤＳ ＡＮＤ ＳＵＲＦＡＣＥＳ Ａ： ＰＨＹＳＩＣＯＣＨＥＭＩＣＡＬ ＡＮＤ ＥＮＧＩＮＥＥＲＩＮＧ ＡＳＰＥＣＴＳ, 1997, Ｖｏｌ．１２５， Ｎｏ．１, ｐｐ．４７−５２ *
JPN5005004894, ＲＵＣＨ Ｆ ｅｔ ａｌ．, ＪＯＵＲＮＡＬ ＯＦ ＣＯＬＬＯＩＤ ＡＮＤ ＩＮＴＥＲＦＡＣＥ ＳＣＩＥＮＣＥ, 20000901, Ｖｏｌ．２２９， Ｎｏ．１, ｐｐ．２０７−２１１, US, ＡＣＡＤＥＭＩＣ ＰＲＥＳＳ *
JPN5005004895, ＧＯＩＡ Ｃ ｅｔ ａｌ．, ＪＯＵＲＮＡＬ ＯＦ ＣＯＬＬＯＩＤ ＡＮＤ ＩＮＴＥＲＦＡＣＥ ＳＣＩＥＮＣＥ, 19981015, Ｖｏｌ．２０６， Ｎｏ．２, ｐｐ．５８３−５９１, US *

Also Published As

Publication number Publication date
US20040028746A1 (en) 2004-02-12
EP1545463B1 (en) 2011-12-21
EP1545463A1 (en) 2005-06-29
CA2494277A1 (en) 2004-02-12
CN100356905C (zh) 2007-12-26
WO2004012710A8 (en) 2005-06-30
CN1674872A (zh) 2005-09-28
ATE537815T1 (de) 2012-01-15
AU2003249195A1 (en) 2004-02-23
WO2004012710A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
CA2458889C (en) A process for preparing crystalline drug particles by means of precipitation
US5573783A (en) Redispersible nanoparticulate film matrices with protective overcoats
US9504652B2 (en) Nanostructured aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them
JP5439182B2 (ja) 化学物質のミセルのナノ粒子
US20100003332A1 (en) Process For Preparing Powder Comprising Nanoparticles of Sparingly Soluble Drug
JPH10513201A (ja) 微結晶のための糖ベース界面活性剤
Li et al. Formulation of nimodipine nanocrystals for oral administration
US12503521B2 (en) Hydroxypropyl methyl cellulose acetate succinate, method for producing the same, and composition for hot-melt extrusion
JP2005536525A (ja) 制御された沈澱（再結晶化）法を用いて、製造された結晶質薬物粒子
JP7716600B2 (ja) 医薬品有効成分の結晶化のための方法
JP2006505518A (ja) 沈澱制御法を用いて製造された結晶質薬物粒子
BRPI0614267A2 (pt) composição de nanopartìculas de 7-t-butóxiiminometilcamptotecina, seu método de produção e uso das referidas nanopartìculas
CN109223722B (zh) 黄体酮纳米晶注射剂及其制备方法
JPWO2007029660A1 (ja) 腸溶性基剤が表面に吸着した難溶性薬物の微小粒子
US20080181957A1 (en) Increased amorphous stability of poorly water soluble drugs by nanosizing
EP3978535A1 (en) Hydroxypropyl methyl cellulose phthalate, method for producing the same, and composition for hot-melt extrusion
Hadke et al. Formulation development and characterization of lyophilized febuxostat nanosuspension
BRPI0815382B1 (pt) Métodos para a produção de uma suspensão de aripiprazol
OA18169A (en) Abiraterone acetate formulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100330

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100907